Join
Live feed
·
PRReleasevia Quantisnow
IDEAYA Biosciences Inc. logo

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update

ByQuantisnow·Wall Street's wire, on your screen.
IDYA· IDEAYA Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IDYA (IDEAYA Biosciences Inc.) and more on Quantisnow.